Table 1. Main characteristics of included and ongoing studies.

Short title	PI	Start/end years	N	Countries	Study status	Benznidazole dose	Comparison	Outcomes
Rodrigues C. 1997[28]	Rodrigues Coura, J.	<1997	77	Brazil	Completed	Adjusted	Nifurtimox/ Placebo	Serology / Xenodiagnoses
E1224[30]	Torrico, F.	2011/2	231	Bolivia	Completed	Adjusted	E1224 / Placebo	PCR
CHAGASAZOL [29]	Molina, C.	2010/1	79	Spain	Completed	Fixed	Posaconazole	PCR
STOP-CHAGAS[17]	Morillo, I.	2011/3	120	Argentina, Chile, México, Guatemala, Spain	Completed	Fixed	Posaconazole / Placebo	PCR
BENDITA[16]	Torrico, F.	2017/8	210	Bolivia	Completed Unpublished	Fixed	E1224 / Placebo	PCR
TRAENA[27]	Riarte, A.	1999/ 2015	910	Argentina	Completed Unpublished	Adjusted	Placebo	PCR Serology Cardiovascular Mortality, Progression
BETTY[32]	Buekens, P.	2019/	600	Argentina	Ongoing	Fixed	Benznidazole 300 mg	PCR
CHICAMOCHA 3[31, 47, 48]	Villar, JC.	2015/	500	Colombia	Ongoing	Adjusted	Nifurtimox/ Placebo	PCR
MULTIBENZ [18]	Molina, I.	2017/	240	Spain, Brazil Argentina, Colombia	Ongoing	Fixed	Benznidazole 150/400 mg	PCR
TESEO[33]	Almeida, IC.	2019	450	Bolivia	Ongoing	Fixed	Benznidazole 150/300 mg Nifurtimox 240/480 mg	RT-PCR